Liquidia Corp. (LQDA)
68.66
+0.03
(+0.04%)
USD |
NASDAQ |
Sep 04, 16:00
68.83
+0.17
(+0.25%)
After-Hours: 20:00
Liquidia Research and Development Expense (Quarterly) : 16.88M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 16.88M |
| March 31, 2026 | 12.27M |
| December 31, 2025 | 16.72M |
| September 30, 2025 | 9.07M |
| June 30, 2025 | 5.94M |
| March 31, 2025 | 6.615M |
| December 31, 2024 | 16.16M |
| September 30, 2024 | 11.58M |
| June 30, 2024 | 9.14M |
| March 31, 2024 | 9.768M |
| December 31, 2023 | 12.55M |
| September 30, 2023 | 7.14M |
| June 30, 2023 | 17.40M |
| March 31, 2023 | 4.978M |
| December 31, 2022 | 4.418M |
| September 30, 2022 | 4.112M |
| June 30, 2022 | 4.819M |
| March 31, 2022 | 4.328M |
| December 31, 2021 | 4.941M |
| Date | Value |
|---|---|
| September 30, 2021 | 4.059M |
| June 30, 2021 | 4.174M |
| March 31, 2021 | 5.531M |
| December 31, 2020 | 4.570M |
| September 30, 2020 | 6.939M |
| June 30, 2020 | 7.766M |
| March 31, 2020 | 10.05M |
| December 31, 2019 | 7.416M |
| September 30, 2019 | 10.27M |
| June 30, 2019 | 10.11M |
| March 31, 2019 | 10.06M |
| December 31, 2018 | 7.999M |
| September 30, 2018 | 7.157M |
| June 30, 2018 | 5.918M |
| March 31, 2018 | 7.627M |
| December 31, 2017 | 6.788M |
| September 30, 2017 | 6.533M |
| June 30, 2017 | 5.258M |
| March 31, 2017 | 6.176M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Indivior Pharmaceuticals, Inc. | 7.00M |
| Harmony Biosciences Holdings, Inc. | 46.60M |
| Johnson & Johnson | 3.603B |
| United Therapeutics Corp. | 146.30M |
| Amneal Pharmaceuticals, Inc. | 39.02M |